Renaissance Technologies
PRLD icon

Renaissance Technologies’s Prelude Therapeutics PRLD Stock Holding History

Renaissance Technologies’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$941K Buy
275,200
+3,900
+1% +$10.2K ﹤0.01% 2307
2025
Q4 		$787K Sell
271,300
-272,700
-50% -$460K ﹤0.01% 2385
2025
Q3 		$783K Sell
544,000
-37,800
-6% -$37.9K ﹤0.01% 2601
2025
Q2 		$471K Sell
581,800
-74,900
-11% -$64.9K ﹤0.01% 2862
2025
Q1 		$504K Buy
656,700
+22,200
+3% +$20.7K ﹤0.01% 2739
2024
Q4 		$809K Buy
634,500
+437,600
+222% +$581K ﹤0.01% 2602
2024
Q3 		$408K Sell
196,900
-9,700
-5% -$44.9K ﹤0.01% 2869
2024
Q2 		$787K Sell
206,600
-38,200
-16% -$155K ﹤0.01% 2454
2024
Q1 		$1.16M Buy
244,800
+28,400
+13% +$110K ﹤0.01% 2393
2023
Q4 		$924K Buy
216,400
+77,026
+55% +$234K ﹤0.01% 2457
2023
Q3 		$431K Sell
139,374
-43,926
-24% -$165K ﹤0.01% 2779
2023
Q2 		$825K Buy
183,300
+44,800
+32% +$268K ﹤0.01% 2583
2023
Q1 		$789K Buy
138,500
+2,000
+1% +$12.2K ﹤0.01% 2625
2022
Q4 		$824K Sell
136,500
-6,900
-5% -$44.2K ﹤0.01% 2650
2022
Q3 		$948K Sell
143,400
-17,086
-11% -$115K ﹤0.01% 2533
2022
Q2 		$838K Buy
160,486
+120,386
+300% +$613K ﹤0.01% 2828
2022
Q1 		$277K Sell
40,100
-87,100
-68% -$797K ﹤0.01% 3506
2021
Q4 		$1.58M Buy
+127,200
New +$2.07M ﹤0.01% 2335

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Renaissance Technologies's PRLD Position: Q1 2026 in Review

Renaissance Technologies increased its Prelude Therapeutics (PRLD) stake by 1.4% in Q1 2026, buying an estimated $10.2K and bringing the position to 275,200 shares worth $941K. The position accounts for ﹤0.01% of the portfolio, ranked #2307.

Renaissance Technologies first reported a position in PRLD in Q4 2021 and has held it in 18 quarters since. The position peaked at $1.58M in Q4 2021. 55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

  • Renaissance Technologies held 275,200 shares of Prelude Therapeutics worth $941K as of Q1 2026.
  • Renaissance Technologies bought 3,900 Prelude Therapeutics shares in Q1 2026, an estimated $10.2K.
  • Prelude Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #2307 holding.
  • Renaissance Technologies first reported a position in Prelude Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • Renaissance Technologies's Prelude Therapeutics position peaked at $1.58M in Q4 2021.
  • 55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.